Go Beyond the Standard of Care
With proven performance you expect from Prospera™
Prospera™ Kidney is a donor-derived cell-free DNA test that evaluates the risk of organ rejection in a simple blood draw. It is a proven early indicator of rejection for early detection, timely intervention and enhanced graft survival.
Prospera™ is a proven leading indicator of rejection
Catch ABMR and TCMR earlier1-3
Assurance for appropriate referrals and biopsy decisions1-4
Performs consistently across patient populations1-4
Previously seen in ProActive study: Predict rejection earlier with cfDNA surveillance backed by robust data
Monitoring with Prospera™ catches antibody-mediated rejection (ABMR), T cell-mediated rejection (TCMR), and mixed rejection months earlier than standard tools for a comprehensive view of rejection status.1
2+ elevated tests correlate with worse eGFR*
- Increased Prospera™ levels in non-rejecting patients are associated with worsening clinical graft function1
Up to 5 months earlier
- Predicts antibody-mediated rejection (ABMR) earlier than biopsy1
Up to 2 months earlier
- Predicts T-cell mediated rejection (TCMR) earlier than biopsy1
New: Prospera™ surveillance shows four distinct trends in the immediate post-rejection period
Four distinct dd-cfDNA patterns—categorized as Low, Drop, Mid, and High—helped differentiate those with favorable prognosis from unfavorable prognosis to rejection treatment, providing a non-invasive molecular lens into post-treatment graft health.5
New: Prospera™ now proven to provide accurate prognosis of long-term outcomes following rejection
Results from the first prospective, multi-center trial to examine how donor-derived cell-free (dd-cfDNA) can be used in post-rejection patient management, the PEDAL study, demonstrated that Prospera™ dd-cfDNA trends post-rejection were shown to be strongly associated with and prognostic of one-year outcomes. Prospera™ may help clinicians identify “favorable prognosis” versus “unfavorable prognosis” post rejection treatment, before changes in serum creatinine levels. In this study, creatinine trends had no statistical correlation with outcomes.5
Favorable Prognosis
Low/dropping Prospera™ levels
- 60x more likely to have positive outcomes5
- Suggests these cases mostly responded to treatment
Unfavorable Prognosis
High/elevated Prospera™ levels
- 97.6% (40/41) experience negative outcomes5
- Suggests these cases did NOT respond to treatment
Optimize treatment decisions with the confidence of strong clinical performance
Using Prospera™ in a surveillance setting accurately identifies active rejection at an earlier, more treatable stage. This can prevent more severe complications, even for patients with unsuspected, subclinical rejection, and enable Prospera™ to help increase the longevity of their transplanted kidneys and to potentially avoid unnecessary biopsies.1,2,6-8
Get highly sensitive rejection risk with Prospera™ with DQS
Prospera™ with DQS is the only donor-derived cell-free DNA (dd-cfDNA) test to provide two dd-cfDNA related indicators on one report: the percentage of donor-derived cfDNA (dd-cfDNA) and DQS. Traditional dd-cfDNA tests report only the fraction of cfDNA from the transplanted kidney. The combination of dd-cfDNA fraction and quantity was found to significantly improve the likelihood ratio than either of these variables alone.8
Receive more data on every report
Prospera™ testing is suggested at regular intervals per each center’s post transplant surveillance protocol to establish an individual baseline for dd-cfDNA levels, which can help detect subclinical rejection earlier.
Discover how Prospera™ with DQS helps inform patient care
Lean on support every step of the way that is convenient for you and your patients
Natera has broad support options to make managing surveillance protocols easy. In all cases, the Natera team is here to help you, your staff, and your patients.
- Rapid tests results delivered within 3–4 days
- Natera’s suite of concierge services and programs
- Covered by Medicare and provides financial support programs
Speak with a Prospera™ expert!
We’re here to help you
*Not actual patient data
1Bromberg JS, et al. Elevation of donor-derived cell-free DNA before biopsy-proven rejection in kidney transplant. Transplantation. 2024;108(9):1994–2004. DOI: 10.1097/TP.0000000000005007.
2Sigdel TK, et al. Optimizing detection of kidney transplant injury by assessment of donor-derived cell-free DNA via massively multiplex PCR. Journal of Clinical Medicine. 2018;8(1):E19.
3Halloran PF, et al. The Trifecta Study: Comparing plasma levels of donor-derived cell-free DNA with the molecular phenotype of kidney transplant biopsies. Journal of the American Society of Nephrology. 2022 Feb;33(2):387–400. DOI: 10.1681/ASN.2021091191.
4Qazi Y, Patel A, Fajardo M, et al. Incorporation of donor-derived cell-free DNA into clinical practice for renal allograft management. Transplantation Proceedings. 2021 Dec;53(10):2866–2872. DOI: 10.1016/j.transproceed.2021.09.027.
5Bunnapradist S, Leca N, Zaky Z, et al. Associations between donor-derived cell-free DNA dynamics and clinical outcomes after kidney allograft rejection: A prospective, multicenter study. American Journal of Transplantation. DOI: 10.1016/j.ajt.2025.07.2470.
6Gauthier PT, Madill-Thomsen KS, Demko Z, et al. Distinct molecular processes mediate donor-derived cell-free DNA release from kidney transplants in different disease states. Transplantation. 2024;108(4):898–910. DOI: 10.1097/TP.0000000000004877.
7Halloran PF, et al. Antibody-mediated rejection without detectable donor-specific antibody releases donor-derived cell-free DNA: Results from the Trifecta Study. Transplantation. 2023 Mar 1;107(3):709–719. DOI: 10.1097/TP.0000000000004324.
8Halloran PF, et al. Combining donor-derived cell-free DNA fraction and quantity to detect kidney transplant rejection using molecular diagnoses and histology as confirmation. Transplantation. June 29, 2022. DOI: 10.1097/TP.0000000000004212.